Press Release

Oct, 19 2023

Increased Prevalence of Chronic Diseases Expected to Drive the Growth of Asia-Pacific Capillary Blood Collection and Sampling Devices Treatment Market

The increased prevalence of chronic diseases is a significant global health concern. These diseases can significantly impact the quality of life of individuals and place a substantial burden on healthcare systems. Capillary blood collection is a common method to obtain small blood samples for various diagnostic tests, such as blood glucose monitoring for diabetes management. In addition, the prevalence of diabetes is rising in the population; hence there is an increased need for regular capillary blood collection for glucose monitoring in affected individuals.

Access Full Report at https://www.databridgemarketresearch.com/zh/reports/asia-pacific-capillary-blood-collection-and-sampling-devices-market

Data Bridge Market Research analyzes that the Asia-Pacific Capillary Blood Collection and Sampling Devices Treatment Market is expected to grow at a CAGR of 7.2% from 2023 to 2030 and reach USD 1,004.64 million by 2030. The blood sampling devices segment is projected to propel the market growth as they are widely used to diagnose chronic disorders in various countries and more due to the availability of more advanced technologies. Especially these blood sampling devices have a broad range of applications for research and clinical purposes.

Key Findings of the Study

Asia-Pacific Capillary Blood Collection and Sampling Devices Treatment Market

Increase in Demand for Safe Blood Collection Technologies

Capillary blood testing requires a smaller amount of blood volume and can be performed easily and quickly. It is preferred over venous sampling in pediatrics to avoid a reduction in blood volume and reduce the risk of anemia. Therefore, 56% of the invasive procedures performed during the neonatal period are capillary blood sampling. It is also preferred by people with severe burns or anxiety about blood testing and those with inaccessible or fragile veins.

Thus, the advantages of capillary blood sampling over venous blood sampling have made this a preferred choice of blood sampling by physicians and patients. Therefore, this creates a demand for better and more efficient capillary collection devices, increasing demand for safe blood collection technologies that act as market drivers.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Year

2021 (Customizable to 2015 – 2020)

Quantitative Units

Revenue in USD Million

Segments Covered

Product (Blood Sampling Devices and Capillary Blood Devices), Modality (Manual Sampling and Automated/Autoinjection Sampling), Material (Plastic, Glass, Stainless Steel, Ceramic, and Others),  Puncture Type (Puncture and Incision), Procedure (Conventional and Point of Care Testing), Age Group (Geriatrics, Infant, Paediatric, and Adult), Test Type (Dried Blood Spot Tests, Plasma/Serum Protein Tests, Comprehensive Metabolic Panel (CMP) Tests, Liver Panel / Liver Profile/ Liver Function Tests, Whole Blood Test, and Others), Application (Cardiovascular Disease, Infectious Diseases, Respiratory Diseases, Metabolic Disorders, and Others), Technology (Volumetric Absorptive Microsampling, Capillary Electrophoresis-Based Chemical Analysis, and Others), End User (Hospitals, Pathology Laboratories, Clinics, Home Care Setting, Blood Banks, Research & Academic Laboratories, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others)

Countries Covered

Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific

Market Players Covered

BD (U.S), TERUMO Corporation (Japan), Thermo Fisher Scientific Inc. (U.S), Cardinal Health (U.S), Owen Mumford Ltd (U.K.), Abbott (U.S.), Nipro (Japan), Greiner Bio-One International GmbH (Austria), Sarstedt AG & Co. KG (Germany), Bio-Rad Laboratories, Inc. (U.S), ICU Medical, Inc. (U.S), CML Biotech (India), Narang Medical Limited (India), Hindustan Syringes & Medical Devices Ltd (India), Sparsh Mediplus (India), B. Braun SE (Germany)  

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis

The Asia-Pacific capillary blood collection and sampling devices market is segmented into eleven notable segments based on product, modality, material, puncture type, procedure, age group, test type, application, technology, end user, and distribution channel.

  • Based on the product, the market is segmented into blood sampling devices and capillary blood collection devices.

In 2023, the blood sampling device segment is expected to dominate the market.

In 2023, the blood sampling devices segment is expected to dominate due to the rising cases of chronic disorders, with a market share of 58.41%.

  •  Based on modality, the market is segmented into manual sampling and automated/autoinjection sampling. In 2023, the manual sampling segment is expected to dominate the market with a market share of 74.45% due to the rise in cases of cardiovascular diseases and other treatments.   

In 2023, the manual sampling segment is expected to dominate the market.

  • Based on material, the market is segmented into plastic, glass, Stainless Steel, Ceramic, and others. In 2023, the plastic segment is expected to dominate the market with a market share of 48.63%.
  • Based on puncture type, the market is segmented into puncture and incision. In 2023, the puncture segment is expected to dominate the market with a market share of 72.64%.
  • Based on procedure, the market is segmented into conventional and point-of-care testing. In 2023, the point-of-care testing segment is expected to dominate the market with a market share of 65.22%.
  • Based on age group, the market is segmented into geriatrics, infant, pediatric, and adult. In 2023, the geriatrics segment is expected to dominate the market with a market share of 41.75%.
  • Based on test type, the market is segmented into dried blood spot tests, plasma/ serum protein tests, comprehensive metabolic panel (CMP) tests, liver panel / liver profile/ liver function tests, whole blood test, and others. In 2023, the whole blood test segment is expected to dominate the market with a market share of 29.57%.
  • Based on application, the market is segmented into cardiovascular disease,  Infectious Diseases, respiratory diseases, metabolic disorder, and others. In 2023, the infectious disease segment is expected to dominate the market with a market share of 42.01%.
  • Based on technology, the market is segmented into volumetric absorptive microsampling, capillary electrophoresis-based chemical analysis, and others. In 2023, the volumetric absorptive microsampling segment is expected to dominate the market with a market share of 56.62%.
  • Based on end user, the market is segmented into hospitals, pathology laboratories, clinics, home care setting, blood banks, research & academic laboratories, and others. In 2023, the hospitals segment is expected to dominate the market with a market share of 26.69%.
  • Based on distribution channel the market is segmented into direct tender, retail sales, and others. In 2023, the direct tender segment is expected to dominate the market with a market share of 53.72%.

Data Bridge Market Research recognizes the following companies as the major capillary market players in the Asia-Pacific capillary blood collection and sampling devices treatment market that include BD (U.S), TERUMO Corporation (Japan), Thermo Fisher Scientific Inc. (U.S), Cardinal Health (U.S), Owen Mumford Ltd (U.K), Abbott (U.S), Nipro (Japan), Greiner Bio-One International GmbH (Austria), Sarstedt AG & Co. KG (Germany), Bio-Rad Laboratories, Inc. (U.S), ICU Medical, Inc. (U.S), CML Biotech (India), Narang Medical Limited (India), Hindustan Syringes & Medical Devices Ltd (India), Sparsh Mediplus (India), B. Braun SE (Germany).

Asia-Pacific Capillary Blood Collection and Sampling Devices Treatment Market

Market Development

  • In June 2023, Cardinal Health announced its collaboration with Signify Health to offer in-home clinical and medication management services through its outcomes business. The company believes that this collaboration helps to reduce costs and eliminate gaps in care.
  • In March 2023, Abbott received FDA clearance for the first commercially available lab-based blood test to help evaluate concussion. The company believes that this will provide clinicians with an objective way to quickly assess individuals with mild TBIs, also known as concussions.
  • In March 2022, ICU Medical, Inc participated in the Raymond James 43rd Annual Institutional Investors Conference. The company believes that this will help in business expansion and strategy development.
  • In January 2020, Nipro Europe Group Companies completed the acquisition of a share of a medical device company in Bangladesh. This acquisition helped the company to improve its financial conditions.
  • In November 2019, Thermo Fisher Scientific Inc. launched the easy-to-use capillary electrophoresis (CE) platform, which utilizes capillary blood samples to obtain forensic results. This launch helped the company to enhance its platform for capillary blood collection devices.

Regional Analysis

Geographically, the countries covered in the Asia-Pacific capillary blood collection and sampling devices treatment market report are Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific.

As per Data Bridge Market Research analysis:

Japan is the fastest growing and dominating country in the Asia-Pacific capillary blood collection and sampling devices market during the forecast period of 2023 to 2030

Japan is expected to dominate the market owing to the higher level of investments by market players and manufacturers and the increasing prevalence of oncological diseases and chronic disorders. Japan will continue to dominate the market in terms of market share and revenue and flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology and the launch of new products in this region. In addition, the increasing number of infectious diseases and rare diseases such as cancer cases and the rising geriatric population are expected further to enhance the market growth rate in this region. 

For more detailed information about the Asia-Pacific capillary blood collection and sampling devices treatment market report, click here –https://www.databridgemarketresearch.com/zh/reports/asia-pacific-capillary-blood-collection-and-sampling-devices-market


Client Testimonials